2023 World Conference on Lung Cancer (Posters)-EP08.02. Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

EP08.02. Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) - PDF(Abstract)

Back to course

Pdf Summary

This study examines the real-world experience of survival outcomes in patients with stage III non-small cell lung cancer (NSCLC) who received consolidation Durvalumab therapy. The study was a retrospective audit of electronic medical records from a single Australian institution, analyzing data from NSCLC patients who started Durvalumab between June 2017 and December 2021. The baseline characteristics of the patient population were analyzed, including age, stage, sex, histology, PD-L1 status, and driver mutation status. The median progression-free survival (mPFS) and overall survival (mOS) were calculated and compared with a historical control group from the same institution.<br /><br />At a median follow-up of 23 months, 56% of patients had experienced progression, 34% had died, and 20% had discontinued Durvalumab due to adverse events. The mPFS was 22.3 months, and the mOS was 43.7 months. Age, ECOG status, PD-L1 expression, early discontinuation, and timing of Durvalumab commencement did not have a statistically significant association with PFS and OS. The historical control group had a mOS of 25.4 months. Among patients who recurred after Durvalumab, subsequent systemic therapies were administered.<br /><br />The study concludes that comparable survival outcomes to those observed in the PACIFIC trial can be achieved in a real-world setting, even with patients being treated outside trial criteria regarding the timing of Durvalumab commencement. Additionally, the introduction of Durvalumab resulted in improved overall survival rates for stage III NSCLC at the institution compared to the historical control group. The study suggests that consolidation Durvalumab therapy can be effective in real-world clinical practice.

Asset Subtitle

Nicole Pringle

Meta Tag

Speaker Nicole Pringle

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

stage III non-small cell lung cancer

NSCLC

consolidation Durvalumab therapy

retrospective audit

electronic medical records

baseline characteristics

progression-free survival

overall survival

adverse events

real-world clinical practice